Clinical Evaluation of Efficacy and Safety of Tofacitinib Film Forming Topical Lotion 2% Versus Momate® Lotion (Mometasone Furoate Topical Solution 0.1% w v) in the Management of Patients with Alopecia Areata - An Open Label, Comparative, Active Controlled, Randomized, Parallel, Prospective, Multi-Center Clinical Study - NI

Hetero Healthcare Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

研究概览

暂无简介。

•1. Patients aged 18 – 50 years of either gender with clinical diagnosis of alopecia areata.
•2. Patients in good health with no evidence of systemic illness.
•3. Willing to report response to treatment as per protocol during the study period.
•4. Willing to give written informed consent.

•1. Any subject who is currently experiencing significant spontaneous regrowth of terminal hair.
•2. Any subject treated with a topical, intralesional or systemic agent likely to cause regrowth in alopecia areata within the past month.
•3. Patients who concomitantly using systemic drugs (steroids, cytotoxic agents (methotrexate, azathioprine), vasodilators, antihypertensive agents, anticonvulsant drugs, beta-adrenergic receptor blockers, diuretics, spironolactone, diazoxide, cyclosporine, or ketoconazole.
•4. Patients with H / O Tuberculosis or any serious illness.
•5. H/ o hypersensitivity to study medication.
•6. Participating in other clinical trials

发起方

Hetero Healthcare Limited